SC 13G: BioAge Labs, Inc.
Ticker: BIOA · Form: SC 13G · Filed: Oct 7, 2024 · CIK: 1709941
| Field | Detail |
|---|---|
| Company | Bioage Labs, INC. (BIOA) |
| Form Type | SC 13G |
| Filed Date | Oct 7, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by BioAge Labs, Inc..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G filing submitted by Bioage Labs, INC. (ticker: BIOA) to the SEC on Oct 7, 2024.
What is the risk level of this SC 13G filing?
This filing has been assessed as low risk.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00001 (ame of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securiti).
How long is this filing?
Bioage Labs, INC.'s SC 13G filing is 5 pages with approximately 1,596 words. Estimated reading time is 6 minutes.
Where can I view the full SC 13G filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,596 words · 6 min read · ~5 pages · Grade level 9.7 · Accepted 2024-10-07 16:16:15
Key Financial Figures
- $0.00001 — ame of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securiti
Filing Documents
- tm2425741d1_sc13g.htm (SC 13G) — 65KB
- tm2425741d1_ex1.htm (EX-99.1) — 8KB
- 0001104659-24-106678.txt ( ) — 74KB
(a). Name of Issuer
Item 1(a). Name of Issuer: BioAge Labs, Inc. (the “ Issuer ”)
(b). Address of Issuer’s Principal Executive Offices
Item 1(b). Address of Issuer’s Principal Executive Offices: 1445A South 50th Street, Richmond, CA 94804
(a). Names of Persons Filing
Item 2(a). Names of Persons Filing: The names of the persons filing this report (collectively, the “ Reporting Persons ”) are: RA Capital Management, L.P. (“ RA Capital ”) Peter Kolchinsky Rajeev Shah RA Capital Healthcare Fund, L.P. (the “ Fund ”)
(b). Address of Principal Business Office or, if None, Residence
Item 2(b). Address of Principal Business Office or, if None, Residence: The address of the principal business office of each of the Reporting Persons is: c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116
(c). Citizenship
Item 2(c). Citizenship: RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United
(d). Title of Class of Securities
Item 2(d). Title of Class of Securities: Common Stock, par value $0.00001 per share (“ Common Stock ”)
(e). CUSIP Number
Item 2(e). CUSIP Number: 09077V100
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether
Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.
Ownership
Item 4. Ownership. The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based upon 35,817,184 shares of Common Stock outstanding as of October 1, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission (the “ SEC ”) on September 26, 2024, after giving effect to an additional 1,650,000 shares issued and sold pursuant to the underwriters’ option. The Reporting Persons ownership of the Issuer’s securities includes (i) 1,810,322 shares of Common Stock directly held by the Fund; and (ii) 400,267 shares of Common Stock directly held by the RA Capital Nexus Fund III, L.P (the “ Nexus Fund III ”). RA Capital Healthcare Fund GP, LLC is the general partner of the Fund and RA Capital Nexus Fund III GP, LLC is the general partner of the Nexus Fund III. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for each of the Fund and the Nexus Fund III and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund or the Nexus Fund III. Each of the Fund and the Nexus Fund III has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in its portfolio, including the shares of the Issuer’s Common Stock reported herein. Because each of the Fund and the Nexus Fund III has divested itself of voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, each of the Fund and the Nexus Fund III disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and th
Ownership of Five Percent or Less of a Class
Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following
Ownership of More than Five Percent on Behalf of Another Person
Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable.
Identification and Classification of Members of the Group
Item 8. Identification and Classification of Members of the Group. Not applicable.
Notice of Dissolution of Group
Item 9. Notice of Dissolution of Group. Not applicable.
Certification
Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit List Exhibit 1: Joint Filing Agreement SIGNATURE After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: October 7, 2024 RA CAPITAL MANAGEMENT, L.P. By: /s/ Peter Kolchinsky Name: Peter Kolchinsky Title: Authorized Signatory PETER KOLCHINSKY /s/ Peter Kolchinsky RAJEEV SHAH /s/ Rajeev Shah RA CAPITAL HEALTHCARE FUND, L.P. By: RA Capital Healthcare Fund GP, LLC Its: General Partner By: /s/ Peter Kolchinsky Name: Peter Kolchinsky Title: Manager